MCID: CRN173
MIFTS: 19

Coronary Heart Disease 8

Categories: Genetic diseases

Aliases & Classifications for Coronary Heart Disease 8

MalaCards integrated aliases for Coronary Heart Disease 8:

Name: Coronary Heart Disease 8 54
Coronary Heart Disease, Susceptibility to, 8 13

Classifications:



External Ids:

OMIM 54 611139

Summaries for Coronary Heart Disease 8

MalaCards based summary : Coronary Heart Disease 8, is also known as coronary heart disease, susceptibility to, 8. An important gene associated with Coronary Heart Disease 8 is CHDS8 (Coronary Heart Disease, Susceptibility To, 8). The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and kidney.

Description from OMIM: 611139

Related Diseases for Coronary Heart Disease 8

Symptoms & Phenotypes for Coronary Heart Disease 8

Clinical features from OMIM:

611139

Drugs & Therapeutics for Coronary Heart Disease 8

Drugs for Coronary Heart Disease 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 546)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
4
Metformin Approved Phase 4 657-24-9 14219 4091
5
Tirofiban Approved Phase 4,Phase 3 144494-65-5 60947
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2 33069-62-4 36314
8
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
9
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
10
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
11
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
12
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
13
Ticagrelor Approved Phase 4,Phase 3,Phase 2 274693-27-5 9871419
14
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1 55142-85-3 5472
15
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2 37350-58-6, 51384-51-1 4171
16
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
17
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-31-9 3440
18
Nicorandil Approved Phase 4 65141-46-0 47528
19
Bisoprolol Approved Phase 4,Phase 1,Phase 2 66722-44-9 2405
20
Doxazosin Approved Phase 4 74191-85-8 3157
21
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
22
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
23
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2 55-63-0 4510
24
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
25
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
26
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
27
Ramipril Approved Phase 4 87333-19-5 5362129
28
Deferiprone Approved Phase 4,Phase 3 30652-11-0 2972
29
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1 7439-89-6 23925
30
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
31
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
32
Lisinopril Approved, Investigational Phase 4,Phase 2 83915-83-7, 76547-98-3 5362119
33
Exenatide Approved, Investigational Phase 4,Phase 3 141758-74-9 15991534
34
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
35
Cilostazol Approved Phase 4 73963-72-1 2754
36
Vancomycin Approved Phase 4 1404-90-6 441141 14969
37
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
38
Dipyridamole Approved Phase 4 58-32-2 3108
39
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
40
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
41
Bupivacaine Approved, Investigational Phase 4,Phase 1 2180-92-9, 38396-39-3 2474
42
Allopurinol Approved Phase 4,Phase 3,Early Phase 1 315-30-0 2094
43
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
44
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
45
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
46
Insulin Aspart Approved Phase 4 116094-23-6 16132418
47
Insulin Glargine Approved Phase 4 160337-95-1
48
Insulin Lispro Approved Phase 4 133107-64-9
49
Zinc Approved Phase 4,Phase 2,Phase 1 7440-66-6 32051 23994
50
Acetaminophen Approved Phase 4 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 832)

id Name Status NCT ID Phase Drugs
1 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
2 GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions Unknown status NCT00220558 Phase 4
3 Effect of Dapagliflozine on Systemic and Renal Endothelial Function Unknown status NCT02501616 Phase 4 Metformin;Dapagliflozin
4 The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention Unknown status NCT00407771 Phase 4 Tirofiban
5 Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS Unknown status NCT01543373 Phase 4
6 Intravascular ULTrasound Guided Versus Conventional Angiography Guided Strategy to Deploy Zotarolimus and Everolimus Eluting Third Generation Stents in the Long Coronary Artery Lesions: ULTRA-ZET Trial Unknown status NCT01979744 Phase 4
7 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
8 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
9 Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial Unknown status NCT02477371 Phase 4
10 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
11 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
12 Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension Unknown status NCT00994617 Phase 4 Losartan and hydrochlorothiazide;Hydrochlorothiazide switched over with Losartan at 8 weeks
13 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
14 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
15 Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
16 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4 Colchicine;Placebo
17 Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome Unknown status NCT02341729 Phase 4 ticagrelor
18 Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy Unknown status NCT01572129 Phase 4 Clopidogrel;Placebo
19 Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines Unknown status NCT00885651 Phase 4 Metoprolole (Selo-Zok ®);Placebo
20 Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
21 Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis Unknown status NCT02048085 Phase 4 Ticagrelor;Clopidogrel
22 Efficacy Study of Nicorandil on Neointima Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
23 Optimum Treatment for Drug-Resistant Hypertension Unknown status NCT02369081 Phase 4 Spironolactone;Bisoprolol;Doxazosin;Placebo
24 Continuous Positive Airway Pressure (CPAP) Treatment in Coronary Artery Disease and Sleep Apnea Completed NCT00519597 Phase 4
25 Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes Completed NCT00599885 Phase 4 telmisartan;valsartan
26 Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone Completed NCT01765452 Phase 4 Closone;Plavix with Astrix
27 Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Completed NCT00589927 Phase 4 cilostazol;placebo
28 Responses of Myocardial Ischemia to Escitalopram Treatment Completed NCT00574847 Phase 4 Escitalopram;Placebo
29 Effect of Probiotic Supplementation on Endothelial Function Completed NCT01952834 Phase 4 Vancomycin
30 Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol Completed NCT01008345 Phase 4 ezetimibe
31 Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial Completed NCT01123291 Phase 4
32 Optimal Stenting Strategy For True Bifurcation Lesions Completed NCT00693251 Phase 4
33 Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
34 Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina Completed NCT01425359 Phase 4 Ranolazine;Ranolazine placebo
35 The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis Completed NCT00332397 Phase 4
36 A Pharmacodynamic Study With Ticagrelor in Hispanic Patients Completed NCT01523366 Phase 4 Ticagrelor;Clopidogrel
37 A Pharmacodynamic Study With Ticagrelor in African American Patients Completed NCT01523392 Phase 4 Ticagrelor;Clopidogrel
38 Choice Of Optimal Strategy For Bifurcation Lesions With Normal Side Branch Completed NCT00694005 Phase 4
39 The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus Completed NCT00235092 Phase 4
40 Different Endurance Training Protocols in Cardiac Rehabilitation Completed NCT01493193 Phase 4
41 Shared Care Rehabilitation After Acute Coronary Syndrome Completed NCT01522001 Phase 4
42 Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions? Completed NCT00376571 Phase 4
43 Study Safety,Efficacy of the Biomime Stent in Patients With Single, Discrete, De Novo, Non-Complex Coronary Lesions Completed NCT01507519 Phase 4
44 Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial Completed NCT00497172 Phase 4
45 The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers Completed NCT00494559 Phase 4 Pioglitazone;Placebo
46 DaVinci Registry(Distinctly Assess Vision in Coronary Intervention) Completed NCT00243438 Phase 4
47 Comparison of Neointimal Coverage Between Zotarolimus Eluting Stent and Everolimus Eluting Stent Completed NCT00894062 Phase 4
48 Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With CAD Completed NCT02382471 Phase 4
49 Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With CAD Completed NCT02117960 Phase 4
50 Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis Completed NCT02215993 Phase 4 Prasugrel;Ticagrelor

Search NIH Clinical Center for Coronary Heart Disease 8

Genetic Tests for Coronary Heart Disease 8

Anatomical Context for Coronary Heart Disease 8

MalaCards organs/tissues related to Coronary Heart Disease 8:

39
Heart, Endothelial, Kidney, Testes, Bone, Liver, Brain

Publications for Coronary Heart Disease 8

Variations for Coronary Heart Disease 8

Expression for Coronary Heart Disease 8

Search GEO for disease gene expression data for Coronary Heart Disease 8.

Pathways for Coronary Heart Disease 8

GO Terms for Coronary Heart Disease 8

Sources for Coronary Heart Disease 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....